1. KPIT Technologies: 

ICICI Direct maintains its ‘Buy’ rating on this software firm with a target price of Rs 1,400, an upside of 11.7%. The company reported strong Q2FY26 results, with revenue up 5.8% YoY to Rs 1,611.3 crore, driven by improvements across US, European, and Asian markets. Analysts Bhupendra Tiwary and Anjini Sharma remain positive, citing growth from the Caresoft and N-Dream acquisitions and rising deal wins.

Management attributes revenue growth to improved client sentiment and renewed traction in autonomous, cybersecurity, after-sales diagnostics, and commercial vehicle programs. However, net profit fell 17% to Rs 169.1 crore due to elevated one-time expenses and finance costs from the Caresoft acquisition. Analysts note KPIT's shift from services to end-to-end solutions and greater use of fixed-price contracts will enhance delivery efficiency and profitability.

Tiwary and Sharma foresee strengthening demand from Europe, India, and China, along with a robust deal pipeline, driving medium-term revenue growth. A 3-year, $100 million deal with a European original equipment manufacturer will ramp up from Q3FY26, supporting near-term revenue. Analysts expect KPIT to deliver revenue and net profit CAGR of 12.3% and 15.9% respectively, over FY26-28.

2. Radico Khaitan:

Emkay retains its ‘Buy’ call on this alcohol manufacturer with a target price of Rs 3,700 per share, an upside of 15.2%. Analysts Nitin Gupta and Mohit Dodeja believe the company's strong execution in driving volumes and easing raw material prices will support both top-line and earnings growth.

Management expects to sustain double-digit volume growth, with its prestige and above (P&A) segment growing 15-20%. It sees good execution as crucial for boosting international market volumes, helped by the D'Yavol Spirits BV acquisition, which adds tequila and scotch to Radico’s portfolio. Analysts note that Radico’s market share in Andhra Pradesh jumped to 30% from 10%.

Gupta and Dodeja emphasise that lower grain prices and vertical integration from its extra-neutral alcohol facility will benefit the company's margins. They add that increasing consumer demand, Radico’s diverse product portfolio, and the potential opening of the Bihar market will boost revenue growth. Analysts expect Radico to deliver a revenue CAGR of 17.2% and a net profit CAGR of 38.3% over FY26-28.

3. PB Fintech:

Geojit BNP Paribas upgrades this software company to a ‘Buy’ rating, with a target price of Rs 2,031, an upside of 8.8%. The company posted strong Q2FY26 results: net profit surged 165% YoY, and revenue grew 38%. Total insurance premiums improved 40% and online new protection business jumped 44%, driving revenue growth.

Management has focused on profitable expansion, aiming for Rs 1 lakh crore in premiums by FY30. It expects higher renewal income to boost profitability. Diversification of the Point-of-Sale Person (PoSP) business across motor and non-motor products has helped expand market share. CEO Yashish Dahiya highlights steady profitability in the United Arab Emirates (UAE), supported by cross-border health insurance demand and improved claims management.

Analyst Antu Eapan Thomas notes that lending disbursals almost doubled, though core lending faced some pressure. He anticipates PB Fintech will sustain strong long-term growth that will come from rising renewal income, increasing online protection penetration, a more balanced PoSP business, and continued UAE strength. Thomas also expects the company's expanding market share to support revenue and profit growth through FY30.

4. Privi Speciality Chemicals: 

Motilal Oswal initiates a ‘Buy’ rating on this chemical manufacturer, with a target price of Rs 3,960, an upside of 25%. Analysts Sumant Kumar and Yash Darak see strong potential, citing the company's solid market position and its ability to meet global demand for aroma chemicals. Privi plans to boost its core production capacity to 66,000 metric tonnes from 48,000 by March 2028.

Management expects the proposed merger with Privi Fine Sciences to enhance its green chemistry portfolio. This merger will add bio-based ingredients like furfural, cyclopentanone, and maltol, used to manufacture fragrances and pharmaceuticals, among other products. The company also anticipates growth from its joint venture with Swiss leader Givaudan, which is building a new plant in Mahad, Maharashtra. This plant will produce complex, high-value molecules under long-term agreements.

Kumar and Darak predict robust growth for Privi, forecasting a 27% revenue CAGR, 34% EBITDA CAGR, and 46% net profit CAGR between FY26-28. They believe expanding capacity and increasing green chemistry product sales will drive profitability. Analysts highlight Privi's move towards high-margin, value-added, green chemistry products, which consistently offer gross margins above 40%.

5. Carysil: 

Anand Rathi maintains its ‘Buy’ rating on this small-cap household products manufacturer with a target price of Rs 1,265, an upside of 27%. Its Q2FY26 results were strong: revenue grew 16% YoY to Rs 2,400 crore, and net profit soared 62% to Rs 272 crore. Robust demand for quartz sinks, stainless steel sinks, and kitchen appliances boosted this, with key segments maintaining high capacity utilisation.

Carysil's management projects about 15% revenue growth for FY26 and expects an 18-20% EBITDA margin. Strong European orders, consistent global brand demand, and ongoing China +1 sourcing benefits drive this outlook. To meet demand, Carysil is expanding, adding 1 lakh quartz sinks by December 2025, increasing stainless steel sink capacity, and boosting faucet production to 1.5 lakh units by Q2FY27. New partnerships with IKEA and Lowe’s should also drive sales volumes.

Analysts Rishab Bothra and Tania Lalla foresee a 17% revenue CAGR and 25% net profit CAGR for FY26-28, driven by rising demand, scale benefits, premiumisation in India, and online sales. Bothra and Lalla noted Carysil has improved its EBITDA margin to 19.2% through better operating efficiency, lower costs, and higher other income.

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)